Camilla Zimmermann, Head of the Division of Palliative Care at the Princess Margaret Cancer Centre, posted on X:
“Urgent need for updated guidelines on Systemic Anticancer Therapy use at End of Life: Our study of 68,000+ patients found use of novel SACT at EOL, including immunotherapy, was associated with indicators of poor-quality.”
Title: Novel Systemic Anticancer Treatments and Health Services Use at the End of Life Among Adults With Cancer
Authors: Javaid Iqbal, Rahim Moineddin, Kieran L. Quinn, Christopher M. Booth, Craig C. Earle, Stephanie Lheureux, Robert Grant, Jenny Lau, Lisa W. Le, Peter Tanuseputro, James Downar, Gary Rodin, Hsien Seow, Jillian Tsai, Robert A. Fowler, Breffni Hannon, Monika K. Krzyzanowska, Camilla Zimmermann
Read The Full Article at Journal of Clinical Oncology.
More posts featuring Cancer.